250 related articles for article (PubMed ID: 12100079)
21. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin.
de Keizer B; Koppeschaar HP; Zelissen PM; Lips CJ; van Rijk PP; van Dijk A; de Klerk JM
Eur J Nucl Med; 2001 Feb; 28(2):198-202. PubMed ID: 11303890
[TBL] [Abstract][Full Text] [Related]
22. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
Campennì A; Pignata SA; Baldari S
Endocrine; 2015 Nov; 50(2):516-8. PubMed ID: 25471282
[TBL] [Abstract][Full Text] [Related]
23. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
24. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic modalities in patients affected by differentiated thyroid carcinoma with high thyroglobulin levels and total body Iodium-131 negative: PET/CT use after recTSH].
Biscontini G; Possa M; Sara R; Milella M; Rossetti C
Minerva Endocrinol; 2004 Dec; 29(4):151-60. PubMed ID: 15765025
[TBL] [Abstract][Full Text] [Related]
26. Clinical importance of anti-thyroglobulin auto-antibodies in patients with differentiated thyroid carcinoma: comparison with 99mTc-MIBI scans.
Küçük ON; Aras G; Kulak HA; Ibiş E
Nucl Med Commun; 2006 Nov; 27(11):873-6. PubMed ID: 17021427
[TBL] [Abstract][Full Text] [Related]
27. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
[TBL] [Abstract][Full Text] [Related]
28. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
[TBL] [Abstract][Full Text] [Related]
29. Comparison of thyroglobulin and radioiodine scintigraphy during follow-up of patients with differentiated thyroid carcinoma.
Johansen K; Woodhouse NJ
Eur J Med; 1992 Nov; 1(7):403-6. PubMed ID: 1341479
[TBL] [Abstract][Full Text] [Related]
30. Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations.
Ramanna L; Waxman A; Braunstein G
J Nucl Med; 1991 Mar; 32(3):441-6. PubMed ID: 2005453
[TBL] [Abstract][Full Text] [Related]
31. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma.
Almeida-Filho P; Ravizzini GC; Almeida C; Borges-Neto S
Clin Nucl Med; 2000 Jun; 25(6):443-6. PubMed ID: 10836693
[TBL] [Abstract][Full Text] [Related]
32. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma.
Dadparvar S; Krishna L; Brady LW; Slizofski WJ; Brown SJ; Chevres A; Micaily B
Cancer; 1993 Jun; 71(11):3767-73. PubMed ID: 8490927
[TBL] [Abstract][Full Text] [Related]
33. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
34. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
35. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
36. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
Ng DC; Sundram FX; Sin AE
J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
[TBL] [Abstract][Full Text] [Related]
37. [Usefulness of isotope diagnosis, ultrasound neck investigation and thyroglobulin assays in quantification of patients operated on for differentiated thyroid cancer and prepared for radioiodine treatment].
Manuszewska-Jopek E; Bolko P; Łacka K; Ruchała M; Oleksa R; Majewski P; Sowiński J
Pol Arch Med Wewn; 2003 Mar; 109(3):265-73. PubMed ID: 12924173
[TBL] [Abstract][Full Text] [Related]
38. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.
Giovanella L; Ceriani L; Ghelfo A; Keller F
Clin Chem Lab Med; 2005; 43(8):843-7. PubMed ID: 16201895
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
Helal BO; Merlet P; Toubert ME; Franc B; Schvartz C; Gauthier-Koelesnikov H; Prigent A; Syrota A
J Nucl Med; 2001 Oct; 42(10):1464-9. PubMed ID: 11585858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
